Mytos
Scaling Regenerative Medicine to Millions of Patients.
Mytos is an automated contract development and manufacturing organization (CDMO) for regenerative medicine, powered by its proprietary iDEM technology. The iDEM platform automates all unit operations in cell culture using standard 2D T flask formats, reducing labor per batch by up to 10x and cutting batch costs by up to 50% compared to manual CDMOs. Mytos offers end-to-end manufacturing services—from process development to regulatory support—without suite fees or device purchase requirements.
Mytos provides automated CDMO services using its iDEM technology, which ports existing manual cell culture protocols into closed automation without altering the biology, enabling scalable and consistent GMP production.
Biotech and cell therapy companies developing regenerative medicine products for clinical and commercial scale
Background.
- Status
- launched
- Business model
- unknown
- Company
- Mytos
Contact
Similar projects.
Editorial take on the space this project sits in — momentum signals, adjacent moves, our call on whether the wedge is real. Get pinged when we publish a new read or when the landscape shifts.
Have a take on this space?
Tell us what you’d build differently, where you think the incumbents miss, or what we’ve gotten wrong about this project. Comments + reactions are coming soon.